Results 131 to 140 of about 258 (197)

Research and validation of forest carbon sequestration measurement model based on biomass method-A case study of Guizhou Province. [PDF]

PLoS One
Min Z, Yang W, Yan Q, Jun Y, Chunling L, Rui RW.   +5 more
europepmc   +1 more source

The Eighth Day of Creation: looking back across 40 years to the birth of molecular biology and the roots of modern cell biology. [PDF]

Mol Biol Cell, 2020
Peifer M.
europepmc   +1 more source

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

Analysis of medieval burials from Ibiza reveals genetic and pathogenic diversity during the Islamic period. [PDF]

Nat Commun
Rodríguez-Varela R, Pochon Z, Mas-Sandoval A, Yaka R, Fortes-Lima CA, García Rubio A, Márquez-Grant N, Marí J, Graziani G, Ferrer Abárzuza A, Vicente M, Lorca-Francisco L, Linderholm A, Lagerholm VK, Arauna LR, Pérez-Ramallo P, Krzewińska M, Schlebusch CM, Götherström A.   +18 more
europepmc   +1 more source

'Deliver This Horse from Evil': The Ritual Aspects of Responses to Veterinary Disease in the Late Middle Ages. [PDF]

Soc Hist Med, 2022
Harrison S.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

A U.S. Pharmacopeia (USP) overview of Pan American botanicals used in dietary supplements and herbal medicines. [PDF]

Front Pharmacol
Upton R, Agudelo I, Cabrera Y, Caceres A, Calderón A, Calzada F, Camacho R, da Costa F, Dobrecky C, Enciso R, Escobar M, Fakhary M, Fletcher E, Gao Q, Lock O, Mata R, Parada M, Perera W, Pombo LM, Reich E, Sanchez E, Simirgiotis MJ, Sood C, Amiguet VT, Villar M, Ghelman R, Schveitzer MC, Portella CFS, Wolffenbüttel A, Ruppelt B, Frickmann FS, Gavillan-Suarez J, Allen K, Alvarado LD, Sarma N, Marles R, Monagas M, Navarro-Hoyos M.   +37 more
europepmc   +1 more source